
## Guillermo MartÃ-n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6994245/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 1744-1750.	2.0	19
2	Impact on Outcomes of Human Leukocyte AntigenÂMatching by Allele-Level Typing in Adults withÂAcute Myeloid Leukemia Undergoing Umbilical CordÂBlood Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 106-110.	2.0	48
3	Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting. Journal of Molecular Diagnostics, 2012, 14, 594-601.	1.2	12
4	Significance of Increased Blastic-Appearing Cells in Bone Marrow Following Myeloablative Unrelated Cord Blood Transplantation in Adult Patients. Biology of Blood and Marrow Transplantation, 2012, 18, 388-395.	2.0	7
5	Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Annals of Hematology, 2012, 91, 1845-1853.	0.8	8
6	Central nervous system involvement at first relapse in patients with acute myeloid leukemia. Haematologica, 2011, 96, 1375-1379.	1.7	28
7	Cord Blood Transplantation from Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 86-94.	2.0	79
8	Single-Unit Umbilical Cord Blood Transplantation fromÂUnrelated Donors in Adult Patients with Chronic Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 1589-1595.	2.0	30
9	Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 730-740.	2.0	54
10	Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica, 2008, 93, 67-74.	1.7	188
11	Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation. Leukemia and Lymphoma, 2007, 48, 2367-2374.	0.6	19
12	The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leukemia Research, 2007, 31, 947-953.	0.4	40
13	A Study of Incidence and Characteristics of Infections in 476 Patients from a Single Center Undergoing Autologous Blood Stem Cell Transplantation. International Journal of Hematology, 2007, 86, 186-192.	0.7	16
14	Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leukemia and Lymphoma, 2006, 47, 1488-1494.	0.6	68
15	Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group. Journal of Clinical Oncology, 2005, 23, 7632-7640.	0.8	126
16	All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood, 2004, 104, 3490-3493.	0.6	98
17	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols Blood, 2004, 104, 2019-2019.	0.6	5
18	Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica, 2004, 89, 926-33.	1.7	97

#	Article	IF	CITATIONS
19	Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Best Practice and Research in Clinical Haematology, 2003, 16, 433-451.	0.7	28
20	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 2003, 103, 1237-1243.	0.6	395
21	Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica, 2003, 88, 19-24.	1.7	135
22	Identification of two atypical PML–RARα transcripts in two patients with acute promyelocytic leukemia. Leukemia Research, 2002, 26, 439-442.	0.4	18
23	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leukemia Research, 2002, 26, 725-730.	0.4	41
24	Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remission. Haematologica, 2002, 87, ECR03.	1.7	4
25	Acute promyelocytic leukemia.Therapy results and prognostic factors. Cancer, 1988, 61, 7-13.	2.0	126